Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NRP1 | O14786 | 3/20 | 0.48 |
| ▸ | C3AR1 | Q16581 | 13/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4569800 | 0.89 | NRP1 (0.49) | NRP1C3AR1LMNAALDH1A1 | |
| SCHEMBL4572300 | 0.84 | NRP1 (0.54) | NRP1LMNAALDH1A1 | |
| SCHEMBL4572286 | 0.81 | C3AR1 (0.56) | C3AR1ALDH1A1 | |
| SCHEMBL4572283 | 0.81 | C3AR1 (0.52) | C3AR1 | |
| SCHEMBL4572250 | 0.79 | NRP1 (0.74) | NRP1 | |
| SCHEMBL10067889 | 0.79 | C3AR1 (0.47) | NRP1C3AR1 | |
| SCHEMBL4572247 | 0.77 | NRP1 (0.50) | NRP1 | |
| SCHEMBL4572249 | 0.74 | NRP1 (0.53) | NRP1 | |
| SCHEMBL4572258 | 0.74 | NRP1 (0.50) | NRP1LMNAALDH1A1 | |
| SCHEMBL11940776 | 0.73 | NRP1 (0.63) | NRP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120269864-A1 | Arginine Derivatives with NP-I Antagonistic Activity | GB06/019611.7 THERAPIES LIMITED (GB) | 2012-10-25 | — | — | US | disclosed |
| US-8227606-B2 | Arginine derivatives with NP-1 antagonistic activity | ARK THERAPEUTICS, LTD. (GB) | 2012-07-24 | — | — | US | disclosed |
| US-20120122862-A1 | ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY | GB06/019611.7 THERAPIES LIMITED (GB) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120269864-A1 | Arginine Derivatives with NP-I Antagonistic Activity | NPFFR1, NPR1, ARG1 | NRP1 145/4885C3AR1 942/4885LMNA 4551/4885 |
| US-20120122862-A1 | ARGININE DERIVATIVES WITH NP-I ANTAGONISTIC ACTIVITY | NPFFR1, NPR1, ARG1 | NRP1 145/4885C3AR1 942/4885LMNA 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.